Online inquiry

IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4798MR)

This product GTTS-WQ4798MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets DPP4 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001379604.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1803
UniProt ID P27487
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4798MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13248MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ12920MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ1074MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ12688MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ12611MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ5058MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ11273MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ2321MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN6000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW